P2RX4 and prostate adenocarcinoma: Using bioinformatics tools (GTEx and UALCAN), we found that the homozygous genetic variant rs25644 contributed to an elevated expression of P2RX4 in the prostate, and P2RX4 was significantly upregulated in patients with prostate adenocarcinoma compared to healthy subjects (P value, 2.23310259173104e−12)31.